An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia.

James L. Januzzi,Joseph M. Garasic,Scott E. Kasner,Vickie McDonald,Mark C. Petrie,Jonathan H. Seltzer,Michael J. Mauro,Kevin Croce,Ellin Berman,Michael W. Deininger,Andreas Hochhaus,Javier Pinilla-Ibarz,Franck E. Nicolini,Dong-Wook Kim,Daniel J. DeAngelo,Hagop M. Kantarjian,Jing Xu,Shouryadeep Srivastava,Daniel Naranjo,Jorge E. Cortes

An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia.

2020

7550Background: The final 5-year analysis of the PACE trial, which evaluated use of PON in pts with refractory chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia, identified a 25% ...

Keywords:

Physical therapy
Occlusive
Oncology
in patient
Leukemia
Ponatinib
Internal medicine
Medicine
Refractory Chronic Myeloid Leukemia
Pathology
Lymphoblastic Leukemia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations